Literature DB >> 25151568

Update on opportunistic infections in the era of effective antiretroviral therapy.

Brian C Zanoni1, Rajesh T Gandhi2.   

Abstract

Despite enormous improvements in effectiveness of treatment for HIV infection, opportunistic infections continue to occur in those who have not yet been diagnosed with HIV and in those who are not receiving antiretroviral therapy. This review focuses on tuberculosis and cryptococcal infections, the most common opportunistic infections (OIs) in patients living with human immunodeficiency virus infection around the world, as well as on new developments in progressive multifocal leukoencephalopathy and pneumocystis pneumonia. In the sections on these conditions, updates on diagnosis, treatment, and complications, as well as information on when to start antiretroviral therapy is provided. The article concludes with a discussion of new data on 2 vaccine-preventable OIs, human papillomavirus and varicella-zoster virus.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiretroviral therapy; Diagnostics; HIV; Opportunistic infections

Mesh:

Substances:

Year:  2014        PMID: 25151568      PMCID: PMC4143780          DOI: 10.1016/j.idc.2014.05.002

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  91 in total

1.  Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis?

Authors:  Viral Vadwai; Catharina Boehme; Pamela Nabeta; Anjali Shetty; David Alland; Camilla Rodrigues
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

2.  Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.

Authors:  Soumya Swaminathan; Chandrasekaran Padmapriyadarsini; Perumal Venkatesan; Gopalan Narendran; Santhanakrishnan Ramesh Kumar; Sheik Iliayas; Pradeep A Menon; Sriram Selvaraju; Navaneetha P Pooranagangadevi; Perumal K Bhavani; Chinnaiyan Ponnuraja; Meenalochani Dilip; Ranjani Ramachandran
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

3.  Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects.

Authors:  Kelly E Dooley; Patrick Sayre; Julie Borland; Elizabeth Purdy; Shuguang Chen; Ivy Song; Amanda Peppercorn; Stephanie Everts; Stephen Piscitelli; Charles Flexner
Journal:  J Acquir Immune Defic Syndr       Date:  2013-01-01       Impact factor: 3.731

Review 4.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors:  Kenneth R Carson; Daniele Focosi; Eugene O Major; Mario Petrini; Elizabeth A Richey; Dennis P West; Charles L Bennett
Journal:  Lancet Oncol       Date:  2009-08       Impact factor: 41.316

5.  Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.

Authors:  Larissa A Wenning; William D Hanley; Diana M Brainard; Amelia S Petry; Kalyan Ghosh; Bo Jin; Eric Mangin; Thomas C Marbury; Jolene K Berg; Jeffrey A Chodakewitz; Julie A Stone; Keith M Gottesdiener; John A Wagner; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

6.  The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

Authors:  A Mocroft; H J Furrer; J M Miro; P Reiss; C Mussini; O Kirk; S Abgrall; S Ayayi; B Bartmeyer; D Braun; A Castagna; A d'Arminio Monforte; B Gazzard; F Gutierrez; I Hurtado; K Jansen; L Meyer; P Muñoz; N Obel; P Soler-Palacin; A Papadopoulos; F Raffi; J T Ramos; J K Rockstroh; D Salmon; C Torti; J Warszawski; S de Wit; R Zangerle; C Fabre-Colin; J Kjaer; G Chene; J Grarup; J D Lundgren
Journal:  Clin Infect Dis       Date:  2013-08-06       Impact factor: 9.079

7.  Elevated lactate dehydrogenase values in patients with Pneumocystis carinii pneumonia.

Authors:  R L Smith; C S Ripps; M L Lewis
Journal:  Chest       Date:  1988-05       Impact factor: 9.410

8.  Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.

Authors:  Richard A Murphy; Vincent C Marconi; Rajesh T Gandhi; Daniel R Kuritzkes; Henry Sunpath
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

9.  Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals.

Authors:  Naasha J Talati; Ulrich Seybold; Bianca Humphrey; Abiola Aina; Jane Tapia; Paul Weinfurter; Rachel Albalak; Henry M Blumberg
Journal:  BMC Infect Dis       Date:  2009-02-10       Impact factor: 3.090

10.  Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial.

Authors:  Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow
Journal:  PLoS One       Date:  2009-05-18       Impact factor: 3.240

View more
  10 in total

Review 1.  HIV infection and immune activation: the role of coinfections.

Authors:  Afroditi Boulougoura; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

2.  Human T-Cell Development and Thymic Egress: An Infectious Disease Perspective.

Authors:  Rachel S Resop; Christel H Uittenbogaart
Journal:  For Immunopathol Dis Therap       Date:  2015

3.  Porcine alveolar macrophage polarization is involved in inhibition of porcine reproductive and respiratory syndrome virus (PRRSV) replication.

Authors:  Longtao Wang; Shouping Hu; Qiang Liu; Yiru Li; Lu Xu; Zhuo Zhang; Xuehui Cai; Xijun He
Journal:  J Vet Med Sci       Date:  2017-09-17       Impact factor: 1.267

4.  A Rare Case of Splenic Pneumocystis jirovecii in a HIV-Positive Patient.

Authors:  Hafsa Abbas; Harish Patel; Ahmed Baiomi; Masooma Niazi; Trupti Vakde; Sridhar Chilimuri
Journal:  Case Rep Gastrointest Med       Date:  2020-06-10

5.  Short- and Long-term Risks of Highly Active Antiretroviral Treatment with Incident Opportunistic Infections among People Living with HIV/AIDS.

Authors:  Yung-Feng Yen; Marcelo Chen; I-An Jen; Pei-Hung Chuang; Chun-Yuan Lee; Su-I Lin; Yi-Ming Arthur Chen
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

6.  Diagnostic Difficulties in a Severely Ill HIV Patient with Multiple Superinfections - A Case Report.

Authors:  Cristina Mănășturean; Cristiana Oprea; Dan Oțelea; Anca Meda Georgescu
Journal:  J Crit Care Med (Targu Mures)       Date:  2019-11-27

7.  Effect of Platycodon grandiflorus Polysaccharide on M1 Polarization Induced by Autophagy Degradation of SOCS1/2 Proteins in 3D4/21 Cells.

Authors:  Liping Li; Xufang Chen; Meiyun Lv; Ziqiang Cheng; Fang Liu; Ying Wang; Aiqin Zhou; Jianzhu Liu; Xiaona Zhao
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

8.  Development of highly active anti-Pneumocystis bisbenzamidines: insight into the influence of selected substituents on the in vitro activity.

Authors:  D Maciejewska; J Żabiński; M Rezler; P Kaźmierczak; M S Collins; L Ficker; M T Cushion
Journal:  Medchemcomm       Date:  2017-10-05       Impact factor: 3.597

9.  Macrophage Polarization in Virus-Host Interactions.

Authors:  Yongming Sang; Laura C Miller; Frank Blecha
Journal:  J Clin Cell Immunol       Date:  2015-04

10.  Candida Species Prevalence Profile in HIV Seropositive Patients from a Major Tertiary Care Hospital in New Delhi, India.

Authors:  Monika Maheshwari; Ravinder Kaur; Sanjim Chadha
Journal:  J Pathog       Date:  2016-03-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.